Cargando…

Elevated Copeptin Levels Are Associated with Heart Failure Severity and Adverse Outcomes in Children with Cardiomyopathy

In children with cardiomyopathy, the severity of heart failure (HF) varies. However, copeptin, which is a biomarker of neurohormonal adaptation in heart failure, has not been studied in these patients. In this study, we evaluated the correlation of copeptin level with functional HF grading, B-type n...

Descripción completa

Detalles Bibliográficos
Autores principales: Karki, Karan B., Towbin, Jeffrey A., Shah, Samir H., Philip, Ranjit R., West, Alina N., Tadphale, Sachin D., Saini, Arun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377870/
https://www.ncbi.nlm.nih.gov/pubmed/37508636
http://dx.doi.org/10.3390/children10071138
_version_ 1785079624925970432
author Karki, Karan B.
Towbin, Jeffrey A.
Shah, Samir H.
Philip, Ranjit R.
West, Alina N.
Tadphale, Sachin D.
Saini, Arun
author_facet Karki, Karan B.
Towbin, Jeffrey A.
Shah, Samir H.
Philip, Ranjit R.
West, Alina N.
Tadphale, Sachin D.
Saini, Arun
author_sort Karki, Karan B.
collection PubMed
description In children with cardiomyopathy, the severity of heart failure (HF) varies. However, copeptin, which is a biomarker of neurohormonal adaptation in heart failure, has not been studied in these patients. In this study, we evaluated the correlation of copeptin level with functional HF grading, B-type natriuretic peptide (BNP), and echocardiography variables in children with cardiomyopathy. Furthermore, we determined if copeptin levels are associated with adverse outcomes, including cardiac arrest, mechanical circulatory support, heart transplant, or death. In forty-two children with cardiomyopathy with a median (IQR) age of 13.1 years (2.5–17.2) and a median follow-up of 2.5 years (2.2–2.7), seven (16.7%) children had at least one adverse outcome. Copeptin levels were highest in the patients with adverse outcomes, followed by the patients without adverse outcomes, and then the healthy children. The copeptin levels in patients showed a strong correlation with their functional HF grading, BNP level, and left ventricular ejection fraction (LVEF). Patients with copeptin levels higher than the median value of 25 pg/mL had a higher likelihood of experiencing adverse outcomes, as revealed by Kaplan–Meier survival analysis (p = 0.024). Copeptin level was an excellent predictor of outcomes, with an area under the curve of 0.861 (95% CI, 0.634–1.089), a sensitivity of 86%, and a specificity of 60% for copeptin level of 25 pg/mL. This predictive value was superior in patients with dilated and restrictive cardiomyopathies (0.97 (CI 0.927–1.036), p < 0.0001, n = 21) than in those with hypertrophic and LV non-compaction cardiomyopathies (0.60 (CI 0.04–1.16), p = 0.7, n = 21).
format Online
Article
Text
id pubmed-10377870
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103778702023-07-29 Elevated Copeptin Levels Are Associated with Heart Failure Severity and Adverse Outcomes in Children with Cardiomyopathy Karki, Karan B. Towbin, Jeffrey A. Shah, Samir H. Philip, Ranjit R. West, Alina N. Tadphale, Sachin D. Saini, Arun Children (Basel) Article In children with cardiomyopathy, the severity of heart failure (HF) varies. However, copeptin, which is a biomarker of neurohormonal adaptation in heart failure, has not been studied in these patients. In this study, we evaluated the correlation of copeptin level with functional HF grading, B-type natriuretic peptide (BNP), and echocardiography variables in children with cardiomyopathy. Furthermore, we determined if copeptin levels are associated with adverse outcomes, including cardiac arrest, mechanical circulatory support, heart transplant, or death. In forty-two children with cardiomyopathy with a median (IQR) age of 13.1 years (2.5–17.2) and a median follow-up of 2.5 years (2.2–2.7), seven (16.7%) children had at least one adverse outcome. Copeptin levels were highest in the patients with adverse outcomes, followed by the patients without adverse outcomes, and then the healthy children. The copeptin levels in patients showed a strong correlation with their functional HF grading, BNP level, and left ventricular ejection fraction (LVEF). Patients with copeptin levels higher than the median value of 25 pg/mL had a higher likelihood of experiencing adverse outcomes, as revealed by Kaplan–Meier survival analysis (p = 0.024). Copeptin level was an excellent predictor of outcomes, with an area under the curve of 0.861 (95% CI, 0.634–1.089), a sensitivity of 86%, and a specificity of 60% for copeptin level of 25 pg/mL. This predictive value was superior in patients with dilated and restrictive cardiomyopathies (0.97 (CI 0.927–1.036), p < 0.0001, n = 21) than in those with hypertrophic and LV non-compaction cardiomyopathies (0.60 (CI 0.04–1.16), p = 0.7, n = 21). MDPI 2023-06-30 /pmc/articles/PMC10377870/ /pubmed/37508636 http://dx.doi.org/10.3390/children10071138 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Karki, Karan B.
Towbin, Jeffrey A.
Shah, Samir H.
Philip, Ranjit R.
West, Alina N.
Tadphale, Sachin D.
Saini, Arun
Elevated Copeptin Levels Are Associated with Heart Failure Severity and Adverse Outcomes in Children with Cardiomyopathy
title Elevated Copeptin Levels Are Associated with Heart Failure Severity and Adverse Outcomes in Children with Cardiomyopathy
title_full Elevated Copeptin Levels Are Associated with Heart Failure Severity and Adverse Outcomes in Children with Cardiomyopathy
title_fullStr Elevated Copeptin Levels Are Associated with Heart Failure Severity and Adverse Outcomes in Children with Cardiomyopathy
title_full_unstemmed Elevated Copeptin Levels Are Associated with Heart Failure Severity and Adverse Outcomes in Children with Cardiomyopathy
title_short Elevated Copeptin Levels Are Associated with Heart Failure Severity and Adverse Outcomes in Children with Cardiomyopathy
title_sort elevated copeptin levels are associated with heart failure severity and adverse outcomes in children with cardiomyopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377870/
https://www.ncbi.nlm.nih.gov/pubmed/37508636
http://dx.doi.org/10.3390/children10071138
work_keys_str_mv AT karkikaranb elevatedcopeptinlevelsareassociatedwithheartfailureseverityandadverseoutcomesinchildrenwithcardiomyopathy
AT towbinjeffreya elevatedcopeptinlevelsareassociatedwithheartfailureseverityandadverseoutcomesinchildrenwithcardiomyopathy
AT shahsamirh elevatedcopeptinlevelsareassociatedwithheartfailureseverityandadverseoutcomesinchildrenwithcardiomyopathy
AT philipranjitr elevatedcopeptinlevelsareassociatedwithheartfailureseverityandadverseoutcomesinchildrenwithcardiomyopathy
AT westalinan elevatedcopeptinlevelsareassociatedwithheartfailureseverityandadverseoutcomesinchildrenwithcardiomyopathy
AT tadphalesachind elevatedcopeptinlevelsareassociatedwithheartfailureseverityandadverseoutcomesinchildrenwithcardiomyopathy
AT sainiarun elevatedcopeptinlevelsareassociatedwithheartfailureseverityandadverseoutcomesinchildrenwithcardiomyopathy